Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27596757 | 0.70 | LTA4H (0.35) | LTA4H | |
| SCHEMBL27606838 | 0.70 | LTA4H (0.35) | LTA4H | |
| SCHEMBL27575444 | 0.69 | LTA4H (0.44) | LTA4H | |
| SCHEMBL28235029 | 0.68 | LTA4H (0.35) | LTA4H | |
| SCHEMBL26155647 | 0.65 | LTA4H (0.33) | LTA4H | |
| SCHEMBL28182726 | 0.62 | CDK5 (0.36) | LTA4H | |
| SCHEMBL5989213 | 0.52 | HSP90AA1 (0.44) | — | |
| SCHEMBL28486037 | 0.48 | — | — | |
| SCHEMBL5988863 | 0.44 | ATM (0.35) | — | |
| SCHEMBL373166 | 0.43 | HSP90AA1 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170183645-A1 | COMPOSITION AND METHOD FOR DIVERSIFYING POLYPEPTIDE LIBRARIES | ABZYME THERAPEUTICS LLC | 2017-06-29 | — | — | US | claimed |
| US-20150119351-A1 | THERAPY OF TUMORS AND INFECTIOUS AGENTS DEFICIENT IN METHYLTHIOADENOSINE PHOSPHORYLASE | LUBIN ADAM (US) | 2015-04-30 | — | — | US | claimed |
| US-8796241-B2 | Therapy of tumors and infectious agents deficient in methylthioadenosine phosphorylase | LUBIN ADAM (US) | 2014-08-05 | — | — | US | claimed |
| US-20120094947-A1 | METHOD FOR THE SELECTIVE THERAPY OF DISEASE | LUBIN ADAM (US) | 2012-04-19 | — | — | US | claimed |
| EP-2192905-A2 | METHOD FOR THE SELECTIVE THERAPY OF DISEASE | Lubin, Adam (US) | 2010-06-09 | — | — | EP | claimed |
| WO-2009032057-A2 | METHOD FOR THE SELECTIVE THERAPY OF DISEASE | LUBIN ADAM (US) | 2009-03-12 | — | — | WO | claimed |
| US-12427151-B2 | Compositions and method of treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-09-30 | — | — | US | disclosed |
| CN-117645968-B | Application of prebiotics in promoting growth of staphylococcus epidermidis CCSM0322 | 上海应用技术大学 | 2024-11-12 | — | — | CN | disclosed |
| CN-117645968-A | Application of prebiotics in promoting growth of staphylococcus epidermidis CCSM0322 | 上海应用技术大学 | 2024-03-05 | — | — | CN | disclosed |
| US-20220241288-A1 | COMPOSITIONS AND METHOD OF TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-08-04 | — | — | US | disclosed |
| US-11260058-B2 | Compositions and method of treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-03-01 | — | — | US | disclosed |
| WO-2021182895-A1 | COSMETIC COMPOSITION FOR INCREASING BENEFICIAL BACTERIA OF SKIN | 주식회사 엘지생활건강 | 2021-09-16 | — | — | WO | disclosed |
| US-10968444-B2 | Methods for generating bispecific functional agents | ABZYME THERAPEUTICS LLC (US) | 2021-04-06 | — | — | US | disclosed |
| US-20060024739-A1 | C. elegans gro-1 gene | HEKIMI SIEGFRIED | 2006-02-02 | — | — | US | disclosed |
| US-6949378-B1 | a polynucleotide encodes a heterologous polypeptide which is green fluorescent protein (GFP) | MCGILL UNIVERSITY (CA) | 2005-09-27 | — | — | US | disclosed |
| JP-2004298190-A | NEW THERMOSTABLE PROTEIN HAVING 6-N-HYDROXYAMINOPURINE METABOLIZING ACTIVITY | OSAKA UNIV | 2004-10-28 | — | — | JP | disclosed |
| WO-2002100530-A2 | METHOD FOR CONTROLLING FERMENTATION | DEGUSSA AG (DE) | 2002-12-19 | — | — | WO | disclosed |
| EP-1059354-A2 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | Ceres Incorporated (US) | 2000-12-13 | — | — | EP | disclosed |
| EP-1009813-A1 | THE PHYSIOLOGICAL CLOCK-RELATED GENES GRO-1, GOP-1, GOP-2, GOP-3, AND HAP-1 | McGILL UNIVERSITY (CA) | 2000-06-21 | — | — | EP | disclosed |
| WO-1999010482-A1 | THE C. ELEGANS GRO-1 GENE | MCGILL UNIVERSITY (CA) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12427151-B2 | Compositions and method of treating cancer | ERCC5, ERCC1, XPA | LTA4H 2247/4885 |
| US-11260058-B2 | Compositions and method of treating cancer | TP53, HCCS, TOP2A | LTA4H 2483/4885 |
| US-20220241288-A1 | COMPOSITIONS AND METHOD OF TREATING CANCER | TP53, POLI, BRCA1 | LTA4H 2421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.